Stock of the Day - March 24, 2020

NeoGenomics (NEO)

$14.61

-$0.23 (-1.5%)

Market Cap: $1.93B

About NeoGenomics

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.

It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

Today's Trend

NeoGenomics, Inc. (NEO) — Shares are trading higher today after a combination of Q1 results, analyst upgrades and a clearer 2026 revenue outlook tied to a MolDX approval. Investors are reacting to revenue strength, commercial execution in oncology testing and multiple price-target upgrades.

Leerink Partners upgraded NEO from "market perform" to "outperform" and raised its price target to $25 (from $12), signaling strong analyst confidence that could attract buying interest. Leerink Partners upgrades NeoGenomics (NEO)
TD Cowen raised its price target to $14 and reiterated a "buy" view, adding further analyst momentum and signaling sizable upside vs. current levels. Benzinga: TD Cowen raises price target
NeoGenomics signaled a 2026 revenue outlook of roughly $797M–$803M following PanTracer Liquid MolDX approval—this formalizes near-term revenue drivers tied to reimbursement and could materially lift top-line estimates. NeoGenomics signals $797M-$803M 2026 revenue outlook following PanTracer Liquid MolDX approval
Q1 results beat on revenue: reported revenue of $186.7M (up ~11% YoY) and met EPS consensus; management highlighted commercial execution and expansion of higher-value tests—fundamental proof that growth levers are working. NeoGenomics’s (NASDAQ:NEO) Q1 CY2026: Beats On Revenue
Investor deep-dive coverage highlights expansion of high-value oncology tests and improving commercial cadence—narrative reinforces why revenue growth may persist as testing mix shifts. NEO Q1 deep dive: High-value test expansion and commercial execution drive oncology growth
Earnings call transcript and highlights provide detail on margin dynamics, utilization trends and guide assumptions—useful for modeling but not new headline-changing information beyond the guidance update. NeoGenomics, Inc. (NEO) Q1 2026 Earnings Call Transcript

Bottom line for investors: the stock is up on a clear combo of revenue beat, stronger near-term revenue guidance tied to MolDX approval, and sizable analyst price-target upgrades. Risks that remain include negative net margins/earnings and valuation sensitivity to execution and reimbursement cadence—monitor upcoming cadence on MolDX rollouts and margin progress.

← Previous Stock of the Day Next Stock of the Day →

NeoGenomics (NEO)

About NeoGenomics

Today's Trend

Recent News